ASCO 2015 Highlights

Wholesale Supply Channels Addressing the Pandemic
By Barry Fortner, PhD; Tommy Pourmahram
COVID-19
AVBCC COVID-19 Webcast Series
Turning from the provision of care to the provision of therapies and essential personal protective equipment (PPE), Mr Pourmahram and Dr Fortner focused on the wholesale supply chain and the challenges of ensuring an uninterrupted flow of crucial materials to areas with the greatest demand.
Read Article
Managed Care Payers During the Pandemic
By Scott Breidbart, MD, MBA; Matthew Eyles; Steven Peskin, MD, MBA, FACP
COVID-19
AVBCC COVID-19 Webcast Series
Dr Peskin, Dr Breidbart, and Mr Eyles gave an overview of the changes the novel coronavirus has prompted for managed care payers. They agreed that the unprecedented set of circumstances surrounding the pandemic has led to an opening of the floodgates to questions without immediate answers, leaving providers and payers in unfamiliar territory in a rapidly changing environment with few guideposts.
Read Article
Pharmaceutical Manufacturers’ Response to COVID-19
By Eric Dozier; Julie Gerberding, MD; Brian Morrissey
COVID-19
AVBCC COVID-19 Webcast Series
The healthcare supply channel is dependent on drug manufacturers and their innovation and production. Representing 3 of the major biopharmaceutical companies, Dr Gerberding, Mr Morrissey, and Mr Dozier discussed the drug manufacturers’ response to the COVID-19 pandemic, announcing a recent collaboration in the fight against the novel coronavirus.
Read Article
Oncology Nursing and Cancer Care
By Brenda Nevidjon, MSN, RN, FAAN; Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
COVID-19
AVBCC COVID-19 Webcast Series
Oncology nurses and nurse navigators are positioned on the front lines of cancer care, playing an integral role in patients’ battles against cancer. Ms Shockney and Ms Nevidjon discussed the rapidly changing world that oncology nurses are facing because of COVID-19.
Read Article
Patient Advocacy During the Pandemic
By Patricia J Goldsmith; Daniel J. Klein
COVID-19
AVBCC COVID-19 Webcast Series
Patient advocacy organizations regularly field and fulfill requests for assistance from patients with a serious illness, such as cancer. In the face of COVID-19, such requests have increased exponentially. Ms Goldsmith and Mr Klein outlined their organizations’ efforts to meet patients’ needs.
Read Article
Oncology Pharmacy Making Adjustments
By Ray Bailey, BPharm, RPh; Michael Reff, RPh, MBA
COVID-19
AVBCC COVID-19 Webcast Series
Mr Reff and Mr Bailey addressed the modifications that oncology pharmacies are making to keep staff and patients safe during the coronavirus pandemic.
Read Article
Revenue Cycle Management in Oncology
By Brian Gockerman, MBA; Parag Shah
COVID-19
AVBCC COVID-19 Webcast Series
Less than a month after California issued a stay-at-home order in response to the COVID-19 crisis, oncology practices are seeing declines in their revenue cycles. Mr Gockerman and Mr Shah analyzed the strategies needed to mitigate the downturn.
Read Article
Unintended Consequences of COVID-19 on Oncology
By Michael Consuelos, MD, MBA, FAAP; Don McDaniel, MBA
COVID-19
AVBCC COVID-19 Webcast Series
Mr McDaniel and Dr Consuelos discussed the likely long-term impact of and lessons for the healthcare industry from the COVID-19 pandemic.
Read Article
April 3, 2020: COVID-19 Impact on the Cancer Care Delivery Ecosystem
April 3, 2020: COVID-19 Impact on the Cancer Care Delivery Ecosystem
By Burt Zweigenhaft, PhD, D.Litt
COVID-19
A discussion articulating the challenges facing cancer care in the current COVID-19 crisis by some of the top thought leaders, faculty, and key opinion leaders.
Read Article
Toxicities Associated with FGFR Inhibitors
Toxicities Associated with FGFR Inhibitors
By Milind M. Javle, MD; Angela Lamarca, MD, PhD, MSc; Vaibhav Sahai, MBBS, MS
Interview with the Innovators, Cholangiocarcinoma
Dr Vaibhav Sahai reviews the toxicities that have been encountered in clinical trials with FGFR inhibitors. He suggests that most of these adverse events are class effects and include hyperphosphatemia (which is relatively easy to manage with dietary restrictions and phosphate-binding agents), nail and hair changes, stomatitis, and retinal epithelial changes. In contrast, Dr Angela LaMarca considers the adverse events associated with chemotherapy, including myelosuppression, nausea, vomiting, diarrhea, and others. Dr Milind Javle suggests that the toxicities encountered with chemotherapy are significantly worse than those with FGFR inhibitors.
Read Article

Page 78 of 330

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.